At the conclusion of this activity, participants will be able to:

1. Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options.

2.Describe the mechanism of action and associated side effects of the new adjuvant therapy.

3. Differentiate the roles between the urologist and medical oncologist in the care of patients with bladder cancer.

4. Discuss the opportunities for the coordination of care between the urologists and medical oncologists.

This educational series is supported by an independent educational grant from:

Bristol Myers Squibb

CME available: https://auau.auanet.org/node/30870